Tricyclic sulfones as RORγ modulators

Patent metadata

Field	Value
Publication number	US-10273259-B2
Application number	US-201715701818-A
Country	US
Kind code	B2
Filing date	Sep 12, 2017
Priority date	May 7, 2015
Publication date	Apr 30, 2019
Grant date	Apr 30, 2019

Abstract

There are described RORγ modulators of the formula (I),

and formula (II)

or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

First claim

What is claimed is:

1. A method of treating psoriasis or psoriatic arthritis in a subject, the method comprising administering to the subject a therapeutically-effective amount of a compound of the formula

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

Assignees

• Bristol Myers Squibb Co

Inventors

• Duan Jingwu
• Dhar T G Murali
• Marcoux David
• Cherney Robert J

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title